From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC) by Lohinai, Zoltán et al.
RESEARCH ARTICLE
From Bench to Bedside: Attempt to Evaluate
Repositioning of Drugs in the Treatment of
Metastatic Small Cell Lung Cancer (SCLC)
Zoltan Lohinai1,7*, Peter Dome2,3, Zsuzsa Szilagyi1, Gyula Ostoros1, Judit Moldvay1,
Balazs Hegedus4,5, Balazs Dome1,4,6☯‡, Glen J. Weiss7☯‡
1 National Koranyi Institute of Pulmonology, Budapest, Hungary, 2 Department of Clinical and Theoretical
Mental Health, Kútvölgyi Clinical Center, Semmelweis University, Budapest, Hungary, 3 National Institute of
Psychiatry and Addictions, Budapest, Hungary, 4 Translational Thoracic Oncology Laboratory, Division of
Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria,
5 Molecular Oncology Research Group, Hungarian Academy of Sciences-Semmelweis University,
Budapest, Hungary, 6 Department of Biomedical Imaging and Image-guided Therapy, Medical University of
Vienna, Vienna, Austria, 7 Western Regional Medical Center, Cancer Treatment Centers of America,
Goodyear, Arizona, United States of America
☯ These authors contributed equally to this work.
‡ BD and GJW are joint senior authors on this work.
* zoltan.lohinai@koranyi.hu
Abstract
Backgrounds
Based on in vitro data and results of a recent drug repositioning study, some medications
approved by the FDA for the treatment of various non-malignant disorders were demon-
strated to have anti-SCLC activity in preclinical models. The aim of our study is to confirm
whether use of these medications is associated with survival benefit.
Methods
Consecutive patients with pathologically confirmed, stage 4 SCLC were analyzed in this ret-
rospective study. Patients that were prescribed statins, aspirin, clomipramine (tricyclic anti-
depressant; TCA), selective serotonin reuptake inhibitors (SSRIs), doxazosin or prazosin
(α1-adrenergic receptor antagonists; ADRA1) were identified.
Results
There were a total of 876 patients. Aspirin, statins, SSRIs, ADRA1, and TCA were adminis-
tered in 138, 72, 20, 28, and 5 cases, respectively. A statistically significant increase in
median OS was observed only in statin-treated patients when compared to those not receiv-
ing any of the aforementioned medications (OS, 8.4 vs. 6.1 months, respectively; p =
0.002). The administration of SSRIs, aspirin, and ADRA1 did not result in a statistically sig-
nificant OS benefit (median OS, 8.5, 6.8, and 6.0 months, respectively). The multivariate
Cox model showed that, besides age and ECOG PS, radiotherapy was an independent sur-
vival predictor (Hazard Ratio, 2.151; 95% confidence interval, 1.828–2.525; p <0.001).
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Conclusions
Results of drug repositioning studies using only preclinical data or small numbers of patients
should be treated with caution before application in the clinic. Our data demonstrated that
radiotherapy appears to be an independent survival predictor in stage 4 SCLC, therefore
confirming the results of other prospective and retrospective studies.
Introduction
Lung cancer is the most frequently diagnosed malignancy worldwide and is a leading cause of
cancer mortality [1]. Importantly, Hungarians have the world’s highest death rates from lung
cancer [2].
Small cell lung cancer (SCLC) is a very aggressive neuroendocrine subtype, and accounts
for 15% [1] of all lung cancers. While the number of new agents and treatment options has
markedly increased in other cancers, for SCLC, chemotherapy remains the main component of
care and no new class of systemic therapy has entered clinical practice in the past three decades
[3]. Patients often present with advanced stage at diagnosis. Surgical resection for a patient
with advanced SCLC is rarely prospectively planned and serves little clinical benefit [4]. Thus,
there is a limited amount of tumor tissue available for molecular analysis and translational
research. Therefore, there remains a large, unmet need of new strategies for drug development.
Drug repositioning which is the identification of old drugs for use in a new indication has
recently led to more rapid and less expensive drug development due to their known dose and
toxicity profile [5]. Based on in vitro and in vivo results of a recent systematic drug reposition-
ing bioinformatics studies, some medications approved by the Food and Drug Administration
(FDA) for the treatment of various non-malignant disorders were demonstrated to have anti-
SCLC activity in preclinical models [6]. Drug dose levels that displayed anti-cancer activity
were similar to those used in the clinic. The side-effect profile of two of these agents, clomipra-
mine and doxazosin, fair better to most chemotherapy for SCLC. Clomipramine, a tricyclic
antidepressant (TCA), has pleiotropic effects, such as serotonin and norepinephrine reuptake
inhibition as well as antagonism of some G-protein coupled receptors (GPCRs), e.g. muscarinic
acethylcholine, histamine H1 and adrenergic α1 receptors) [7]. Doxazosin, a selective
α1-adrenergic receptor (ADRA1) antagonist, led to decreased cell survival and inhibition of
downstream signaling [6].
The antidepressant fluoxetine, a selective serotonin reuptake inhibitor (SSRI), has demon-
strated Ca2+ independent apoptosis in cancer cells [8] and acts at the serotonin pathway simi-
larly to the TCAs, disrupting autocrine survival signals involving neurotransmitters and their
GPCRs [6, 9].
Statins, commonly used cholesterol-lowering agents in clinical practice, act on the Ras path-
way [10], have anti-proliferative, pro-apoptotic, and anti-metastatic effects in SCLC [11]. Stat-
ins have been reported to reduce the incidence of lung cancer and also increase the survival of
patients with lung cancer [12]. Anti-inflammatory and anti-platelet drugs like aspirin may play
an important role in preventing cancer risk and progression possibly by the involvement of
cyclooxygenase-2 in the pathogenesis of lung cancer [13].
Nevertheless, the clinical relevance of these drugs for the treatment of metastatic SCLC
remains unclear. The aim of our study is to evaluate whether the use of these medications is
associated with survival benefit in a large, well-defined cohort of metastatic SCLC patients
from a single institution.
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Materials and Methods
Ethics Statement
The study was conducted based on the ethical standards prescribed by the Helsinki Declaration
of the World Medical Association and with the approval of the national level ethics committee
(Hungarian Scientific and Research Ethics Committee of the Medical Research Council [ETT
TUKEB]). The approval number is 52614-4/2013/EKU. Patient consent is not required and
was not obtained for this study, concerning retrospective study of existing data. Patients were
de-identified and the clinical information were collected. Patients cannot be identified either
directly or indirectly.
Study Population
Consecutive patients with cytologically or histologically confirmed, metastatic (TanyNanyM1)
SCLC evaluated at the National Koranyi Institute of Pulmonology between 2000–2013 were
analyzed in this retrospective study. Patients that were prescribed statins, aspirin, clomipra-
mine, SSRIs, doxazosin and prazosin were identified. Information collected included prescrip-
tion of the above medications, clinicopathological characteristics (including gender, age,
Eastern Cooperative Oncology Group performance status [ECOG PS]), applied chemo- and
radiotherapy, and overall survival (OS). TNM stage according to the Union for International
Cancer Control (7th edition)[14], ECOG PS, and age were evaluated at the time of diagnosis.
Treatment
Patients were treated first-line with a platinum-etoposide doublet regimen or with a combina-
tion of cyclophosphamide, epirubicin, and vincristine (CEV). Radiation therapy (RT) including
thoracic RT, prophylactic cranial irradiation (PCI), or whole brain radiation therapy (WBRT)
were administered to selected patients. The study and all treatments were conducted in accor-
dance with contemporary NCCN guidelines.
Statistical Methods
OS was estimated from the time of diagnosis in patients presenting with metastatic stage IV
disease, until death or last available follow-up. Date of last follow-up included in this analysis
was February 15, 2015. Patients were grouped according to prescribed medications and com-
pared to those in the control group (patients not on any of the highlighted medications).
Kaplan-Meier curves and two-sided log-rank tests were used for univariate survival analyses.
Age (<70 yrs vs.70 yrs) was considered as a categorical variable. The Cox proportional haz-
ards model was used for uni- and multivariate survival analyses to calculate the hazard ratios
(HR) and corresponding 95% confidence intervals (CI). To address the problem of multiple
comparisons, Bonferroni’s correction was applied. Thus, with eight confounding variables (e.g.
gender, age, ECOG PS, RT, aspirin, statins, SSRIs, and ADRA1 [doxazosin and prazosin were
grouped together since both are ADRA 1 antagonists]), p-values less than 0.00625 were consid-
ered to indicate statistical significance. All p-values were two-sided. All variables with p-values
less than 0.00625 were included in the multivariate analysis. For multivariate survival analyses,
the Cox regression model was adjusted for age as a categorical variable (<70 yrs vs.70 yrs),
ECOG PS (0–1 vs.>1), statin treatment, and RT. Metric data are shown as median or mean
and corresponding range or, in case of OS, as median and corresponding 95% CI. Clinical char-
acteristics of patients prescribed statins compared to the control group or RT vs. non-RT were
analyzed by the Chi-square test, while ages were compared using the Student’s t-test. All
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statistical analyses were performed using the PASW Statistics 18.0 package (SPSS Inc., Chicago,
IL, USA).
Results
The patient clinical characteristics are shown in Table 1 and S1 Table. There were a total of 876
Caucasian patients (508 men and 368 women) with a median age of 61 years (range, 33–86).
First-line platinum-etoposide chemotherapy and second-line chemotherapy was administered
in 65% and 39.9% of the cases; respectively. The median follow-up was 6.5 months (range,
0–150 months) with 868 deaths out of 876 patients. Aspirin, statins, SSRIs, ADRA1, and TCA
were prescribed in 138, 72, 20, 28, and 5 cases; respectively (S1 Table). Statin and aspirin were
concurrently prescribed in 36 cases (among them SSRIs and ADRA1 were also administered in
2 and 4 cases; respectively), while aspirin and SSRIs or ADRA1 were concurrently prescribed
in 1 and 5 cases, respectively. Gender, age, ECOG PS, and different treatments were tested for
predicting OS.
Univariate analysis with Bonferroni’s correction identified age, ECOG PS, statin treatment,
and radiation therapy as significant prognostic factors (Figs 1 and 2, Tables 2 and 3). Age< 70
yrs (vs.70 yrs) conferred a significantly improved OS (p<0.001; Fig 1A). Patients with
ECOG PS 0–1 had significantly better OS than those presenting with ECOG PS>1 (p<0.001;
Fig 1B). Among medications of various non-malignant disorders, a statistically significant
increase in OS was observed in statin-prescribed patients when compared to those not pre-
scribed any of the aforementioned medications (median OS, 8.4 vs. 6.1 months; respectively;
p = 0.002; Fig 2D, Tables 2 and 3).
Next, the clinicopathological characteristics were compared in the statin versus the control
group (S1 Table). Patients with a statin prescription had significantly better performance status
Table 1. Major clinical characteristics of metastatic SCLC patients received radiation therapy (RT) versus patients not treated with RT (n = 876).
RT Non-RT p-value
Total 299 577
Age (mean±SD) 59.7 ± 8.6 62.5 ± 9 <0.001
Gender
Male 173 (58%) 335 (58%) n.s
Female 126 (42%) 242 (42%)
ECOG PS
0–1 218 (73%) 362 (63%) 0.003
>1 81 (27%) 215 (37%)
Chemotherapy
Platinum-etoposide 224 (75%) 295 (52%) <0.001
CEV 73 (24%) 211 (36%)
Unknown data/ best supportive care 2 (1%) 71 (12%) -
Radiation therapy
PCI 30 - -
WBRT 174 - -
Thoracic RT 158 - -
Median OS (95%CI) months 10.0 (8.9–10.9) 4.8 (4.3–5.4) -
Data shown in parentheses are column percentages. ECOG PS: Eastern Cooperative Oncology Group performance status; OS: overall survival; CEV:
cyclophosphamide, epirubicin, vincristine; PCI: prophylactic cranial irradiation; WBRT: whole brain radiation therapy.
doi:10.1371/journal.pone.0144797.t001
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(ECOG PS 0–1, 76% vs. 63%, P = 0.03) and received significantly more first line platinum-eto-
poside therapy, PCI, and WBRT compared to the control group (78% vs. 61%; 13% vs. 2%;
33% vs. 19%; p values were below 0.001 in all cases). Prescriptions for statins were significantly
associated with those patients receiving 2nd line chemotherapy compared to the control group
(53% vs. 39%, P = 0.025, Chi-square test, S2 Table). In contrast, treatment with other classes of
drugs was not more frequent in patients receiving 2nd line chemotherapy.
Furthermore, significantly increased median OS was observed in patients received RT when
compared to those did not receive RT (10.0 vs. 4.8 months; respectively; p<0.001; Fig 1D). In
contrast, the administration of SSRIs, aspirin, and ADRA1s did not result in a statistically sig-
nificant OS benefit (median OS values were 8.5, 6.8, and 6.0, respectively (vs. 6.1 months in
controls; Fig 2). The median OS was 7.2 months in the clomipramine group. Additionally,
there was no significant difference in the OS by gender (Fig 1C). The multivariate Cox model
showed that besides age and ECOG PS, RT was an independent survival predictor (HR, 2.151;
95% CI, 1.828–2.525; p<0.001; Table 3).
Next, the clinicopathological characteristics were compared in the RT vs. the non-RT group
(Table 1). Patients received RT had significantly better performance status (ECOG PS 0–1,
73% vs. 63%; p = 0.003; Table 1), had younger age (59 vs. 62 yrs; p<0.001; Table 1), and
Fig 1. Kaplan-Meier curves for the OS of clinical variables of metastatic SCLC patients. (A) age <70 yrs vs.70yrs (p = 0.001), (B) ECOG PS 0–1 vs.
ECOG PS >1 (p<0.001), (C) male (vs. female; p = 0.021), and (D) radiation therapy (RT) vs. patients not treated with RT (p<0.001).
doi:10.1371/journal.pone.0144797.g001
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received significantly more platinum-etoposide therapy (75% vs. 52%; respectively; p<0.001;
Table 1) compared to all other patients.
Discussion
In the last three decades, no new class of systemic therapy has entered clinical practice for
advanced SCLC. Therefore, our study represents a strategy designed to evaluate a recent sys-
tematic drug repositioning bioinformatics study and different FDA approved medications
with preclinical anti-SCLC activity in a clinical setting [6, 9, 10, 13]. This is one of the largest
Fig 2. Kaplan-Meier curves for the OS of metastatic SCLC patients. Effect of FDA approved drugs. (A) Aspirin (vs. control; p = 0.225), (B) doxazosin
and prazosin (vs. control; p<0.479), (C) selective serotonin reuptake inhibitors (SSRIs) (vs. control; p = 0.195), (D) statin treatment vs. control (p = 0.002) and,
(E) clomipramine (a tricyclic antidepressant; TCA) vs. control had no effect on OS.
doi:10.1371/journal.pone.0144797.g002
Table 2. Univariate survival analysis of studied drugs in metastatic SCLC. (n = 876).
Univariate
Prognostic factor HR 95% CI p-value
aspirin 0.9443 0.7854–1.135 0.5423
SSRIs 0.7765 0.5198–1.160 0.2165
ADRA1 0.9032 0.6244–1.306 0.5886
statins 1.477 1.156–1.890 0.002
TCA 0.9572 0.4036–2.271 0.921
SSRIs: selective serotonin reuptake inhibitors; ADRA1: α1-adrenergic receptor antagonists (doxazosin and
prazosin), TCA: tricyclic antidepressant (clomipramine).
Two-sided log-rank tests were used for univariate survival analyses
doi:10.1371/journal.pone.0144797.t002
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analyses of a well-defined metastatic SCLC cohort with a long-term follow-up. We analyzed
whether the prescription of various medications was associated with survival benefit in a Hun-
garian cohort of patients, from a region with a high prevalence of lung cancer [2].
In this study, among reported standard prognostic parameters, only age<70 yrs and ECOG
PS 0–1 proved to be an independent prognostic factor associated with longer OS similar as
reported by others [15]. Female gender was not an independent survival predictor [16]. The
increase in median OS remained significant in the multivariate analysis among patients received
RT (besides age and ECOG PS). However, these patients had significantly better performance
status (ECOG PS 0–1, 73% vs. 63%; p = 0.003; Table 1), were on average younger (59 vs. 62 yrs;
p<0.001; Table 1), and received significantly more platinum-etoposide therapy compared to
those not on RT (75% vs. 52%; respectively; p<0.001; Table 1). To date, increased OS for chemo-
therapy in SCLC was observed only in elderly patients [17]. The most recent NCCN guideline
version I. 2015 reports no evidence of superiority among first-line chemotherapeutic agents.
Our findings are in line with others that show that RT in SCLC is associated with survival benefit
[18, 19]. The median OS of patients in the control group for medications listed in the methods
section was 6.1 months, lower than OS from previously published data (7.1–9.4 months). This
discrepancy is possibly due to the fact, that we included only metastatic patients (TanyNanyM1)
in our study.”In the univariate analysis, a statistically significant increase in OS was observed in
statin-prescribed patients when compared to the control group (median OS, 8.4 vs. 6.1 months;
respectively; p = 0.002; Fig 1C). Of note, this difference did not remain significant in the multi-
variate analysis when RT was added as a confounding variable into Cox model. However, in a
phase 2 study of 61 SCLC patients that received simvastatin in combination with irinotecan and
cisplatin, there was improved survival in heavy smokers [16]. Furthermore, preclinical data in
non-small cell lung cancer (NSCLC) reported that mTOR-dependent, statin-induced inhibition
of Akt phosphorylation and nuclear translocation sensitizes cells to etoposide and other cyto-
static drugs which supports our clinical findings [20]. This is in line with a very recent survey
from Ireland, reporting that lung cancer patients prescribed simvastatin had reduced rates of
cancer-specific mortality [12]. In contrast, a recent trial found no protective effect of pravastatin
and chemotherapy compared with chemotherapy alone in SCLC patients [21]. Other previous
reports were unable to demonstrate a statistically significant survival benefit [16, 22].
In the group of patients prescribed aspirin, the median OS was not significantly increased
(6.8 vs. 6.1 months in control; Fig 2A). This finding is in line with a recent drug repositioning
bioinformatical study that did not identify aspirins as candidate drugs with predicted efficacy
against SCLC [6] or an earlier study that found no effect of aspirin on tumor progression [23].
A study from Poland in unilateral SCLC found a 1.5 fold greater probability of survival in
patients receiving various antiplatelet drugs, including aspirin [24]. This discrepancy could be
explained by the lower stage of disease analyzed compared to our population.
Table 3. Clinical variables and survival of patients with metastatic SCLC in the Cox proportional hazardsmodel.
Univariate Multivariate
Prognostic factor HR 95% CI p-value HR 95% CI p-value
Age (<70 yrs vs. 70 yrs) 1.590 1.341–1.886 <0.001 1.358 1.119–1.647 0.002
ECOG PS (0–1 v >1) 1.675 1.452–1.931 <0.001 1.652 1.412–1.933 <0.001
Statins 1.477 1.156–1.890 0.002 1.094 0.851–1.408 0.483
Radiation therapy 2.160 1.876–2.500 <0.001 2.151 1.828–2.525 <0.001
HR: hazard ratio; CI: conﬁdence interval; ECOG PS: Eastern Cooperative Oncology Group performance status.
doi:10.1371/journal.pone.0144797.t003
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Of note, based on our results and number of patients in subgroups, we were not able to
prove any significant survival benefit with prescribed medications acting on the GPCRs consid-
ered to be most relevant in SCLC by in vitro, in vivo, and in silico approaches [6]. Bearing in
mind some limitations of the study, neither selective agents nor medications acting on multiple
targets with the highest expectations in efficacy appeared to have increased OS. SSRIs did not
show a significant increase of median OS (vs. control; 8.5 vs. 6.1 months; respectively; Fig 2C).
We identified only 5 patients in the multitarget GPCR and monoamine transporter blocker clo-
mipramine group (vs. control; median OS, 7.2 vs. 6.1 months; respectively; Fig 2E). Based on
this limitation, we were not able to perform a statistical analysis, and therefore, to draw a firm
conclusion. In a recent phase IIa clinical trial of second-line desipramine, there was rapid
tumor progression and no clinical benefit for five patients with high grade neuroendocrine
tumors [25, 26]. The investigators hypothesized that the different type of TCAs administered
may have led to discordant outcome with preclinical findings (imipramine, clomipramine).
The neurocognitive side effects led to intermittent and early discontinuation of the treatments
and closure of the trial.
Our results show that ADRA1 antagonists did not appear to improve OS (median OS, 6.0
months (vs. 6.1 months in controls)). Our findings are in contrast to in silico data that demon-
strated anti-SCLC activity [6]. This discrepancy is possibly caused by the unique biology, het-
erogeneity, and broad spectrum of neuroendocrine patterns of SCLC. Additional reasons to
include: differences in the cancer microenvironment, and the administration and metabolism
of the drug in vivo compared to the human body.
Due to its retrospective nature our study has several limitations. We were not able to verify
medication compliance and duration of use. In addition, statins were prescribed more fre-
quently during the latter years of this study period coinciding with the advance of the supportive
oncology care, which may have contributed to the increased survival of those patients. Further-
more, it remains unclear whether a statin itself confers a more benign behavior of SCLC,
decreases cardiovascular morbidity and mortality, or access to minimally invasive cardiology
procedures which overlaps during the time period with more frequent statin prescribing pat-
terns leads to improved survival. Furthermore, we did not have data on clinical depression, and
thus, we were not able to use a more appropriate control group (e.g. patients with untreated
major depression) for patients on antidepressants. This would have been of particular interest
since it is well known that depression may negatively influence cancer patient survival [27].
Accordingly, it is conceivable that in our sample the possible survival benefit associated with
antidepressant (TCA or SSRI) treatment was offset by depression itself. Although, compared to
the control group OS values were also longer for the SSRIs and the TCA subgroups, the sample
sizes were especially small in these two subgroups, which should also be considered as a possible
limitation. Finally, compared to the control group a significantly higher proportion of subjects
within the statin group received RT (a treatment modality results in prolonged survival in
SCLC) which may decrease the validity of our conclusion on the positive effect of statins on sur-
vival [18][19].
Improving overall survival in SCLC is extremely difficult and has plagued drug development
for this disease. It further explains the reason that no new class of systemic therapy has entered
clinical practice over decades. Therefore, and more importantly, our study addresses an impor-
tant issue in a unique way. After accounting for several limitations, among them the retrospec-
tive nature of our study, statins appear to provide a statistically significant survival benefit in
the univariate analysis in metastatic SCLC. However, in the multivariate setting among thera-
pies only RT appears to be an independent prognosticator for increased OS. Of course, studies
with prospective designs and appropriately matched control subjects are needed to confirm
our results on the beneficial effect of statin administration on the course of SCLC. Other classes
Drug Repositioning in Metastatic Small Cell Lung Cancer
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of medications analyzed in this study did not validate the results of preclinical drug reposition-
ing studies previously reported, suggesting that the results of drug repositioning studies using
only preclinical data or small numbers of patients should be treated with caution before appli-
cation in the clinic.
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S1 Table. Major clinicopathological characteristics of patients received FDA- approved
drugs of various non-malignant disorders reported to have potential anti-SCLC activity.
Data shown in parentheses are column percentages. ECOG PS: Eastern Cooperative Oncology
Group performance status;OS: overall survival; TCA: tricyclic antidepressant (clomipramine),
SSRIs: selective serotonin reuptake inhibitors; CEV: cyclophosphamide, epirubicin, vincristine;
PCI: prophylactic cranial irradiation;WBRT: whole brain radiation therapy; ADRA1: α1-adren-
ergic receptor antagonists (doxazosin and prazosin).
(PDF)
S2 Table. Distribution of prescribed study drugs according to the different lines of
chemotherapy. SSRIs: selective serotonin reuptake inhibitors; ADRA1: α1-adrenergic receptor
antagonists (doxazosin and prazosin), TCA: tricyclic antidepressant (clomipramine), CHT:
chemotherapy. Two-sided log-rank tests were used for univariate survival analyses. there was
no data in the case of 12 patients on chemotherapy administration and 61 patients received
best supportive care.
(PDF)
Acknowledgments
The authors thank the patients and clinical teams.
The authors were supported by Lung Cancer Research Scholarship of the Hungarian Society
of Pulmonology 2015 (ZL); ESMO Translational Research Fellowship 2015 (ZL); Janos Bolyai
Research Scholarship of the Hungarian Academy of Sciences (PD).
Author Contributions
Conceived and designed the experiments: ZL PD BH GJW. Performed the experiments: ZL PD
ZS GO JM GJW. Analyzed the data: ZL PD GO JM BH BD GJW. Contributed reagents/materi-
als/analysis tools: GO BD GJW. Wrote the paper: ZL PD JM BH BD GJW.
References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9–29. doi: 10.
3322/caac.21208 PMID: 24399786.
2. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer Incidence and Mortality Worldwide, International
Agency for Research on Cancer, available from: http://globocan.iarc.fr, accessed on 13th December
2013.
3. Kalemkerian GP. Advances in pharmacotherapy of small cell lung cancer. Expert opinion on pharmaco-
therapy. 2014; 15(16):2385–96. doi: 10.1517/14656566.2014.957180 PMID: 25255939.
4. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial
to determine the benefit of surgical resection of residual disease following response of small cell lung
cancer to combination chemotherapy. Chest. 1994; 106(6 Suppl):320S–3S. PMID: 7988254.
5. Jiao M, Liu G, Xue Y, Ding C. Computational drug repositioning for cancer therapeutics. Curr Top Med
Chem. 2015; 15(8):767–75. PMID: 25732789.
6. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, et al. A drug repositioning
approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other
Drug Repositioning in Metastatic Small Cell Lung Cancer
PLOS ONE | DOI:10.1371/journal.pone.0144797 January 6, 2016 9 / 11
neuroendocrine tumors. Cancer Discov. 2013; 3(12):1364–77. doi: 10.1158/2159-8290.CD-13-0183
PMID: 24078773; PubMed Central PMCID: PMC3864571.
7. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British
journal of pharmacology. 2007; 151(6):737–48. doi: 10.1038/sj.bjp.0707253 PMID: 17471183; PubMed
Central PMCID: PMC2014120.
8. Lin KL, Chou CT, Cheng JS, Chang HT, LiangWZ, Kuo CC, et al. Effect of fluoxetine on [Ca(2)(+)]i and
cell viability in OC2 human oral cancer cells. Chin J Physiol. 2014; 57(5):256–64. doi: 10.4077/CJP.
2014.BAC208 PMID: 25241985.
9. Teicher BA. Targets in small cell lung cancer. Biochem Pharmacol. 2014; 87(2):211–9. doi: 10.1016/j.
bcp.2013.09.014 PMID: 24091017.
10. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, Arcaro A. Potent inhibition of small-cell lung
cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling.
Oncogene. 2006; 25(6):877–87. doi: 10.1038/sj.onc.1209117 PMID: 16170339.
11. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist. 2006;
11(3):306–15. doi: 10.1634/theoncologist.11-3-306 PMID: 16549815.
12. Cardwell CR, Mc Menamin U, Hughes CM, Murray LJ. Statin use and survival from lung cancer: a popu-
lation-based cohort study. Cancer Epidemiol Biomarkers Prev. 2015; 24(5):833–41. doi: 10.1158/1055-
9965.EPI-15-0052 PMID: 25934831.
13. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM. Inflammation in lung carcinogene-
sis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol. 2008; 66
(3):208–17. doi: 10.1016/j.critrevonc.2008.01.004 PMID: 18304833; PubMed Central PMCID:
PMC2483429.
14. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E Jr. The 7th lung cancer TNM classification
and staging system: Review of the changes and implications. World J Radiol. 2012; 4(4):128–34. Epub
2012/05/17. doi: 10.4329/wjr.v4.i4.128 PMID: 22590666; PubMed Central PMCID: PMC3351680.
15. Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, et al. Significance of programmed cell
death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J
Thorac Oncol. 2015; 10(3):426–30. doi: 10.1097/JTO.0000000000000414 PMID: 25384063.
16. Han JY, Lim KY, Yu SY, Yun T, Kim HT, Lee JS. A phase 2 study of irinotecan, cisplatin, and simva-
statin for untreated extensive-disease small cell lung cancer. Cancer. 2011; 117(10):2178–85. doi: 10.
1002/cncr.25790 PMID: 21523731.
17. Caprario LC, Kent DM, Strauss GM. Effects of chemotherapy on survival of elderly patients with small-
cell lung cancer: analysis of the SEER-medicare database. J Thorac Oncol. 2013; 8(10):1272–81. doi:
10.1097/JTO.0b013e3182a007ba PMID: 24457238; PubMed Central PMCID: PMC3901951.
18. Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic
radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet.
2015; 385(9962):36–42. doi: 10.1016/S0140-6736(14)61085-0 PMID: 25230595.
19. ZhangW, JiangW, Luan L, Wang L, Zheng X, Wang G. Prophylactic cranial irradiation for patients with
small-cell lung cancer: a systematic review of the literature with meta-analysis. BMC cancer. 2014;
14:793. doi: 10.1186/1471-2407-14-793 PMID: 25361811; PubMed Central PMCID: PMC4232715.
20. Roudier E, Mistafa O, Stenius U. Statins induce mammalian target of rapamycin (mTOR)-mediated inhi-
bition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther. 2006; 5
(11):2706–15. doi: 10.1158/1535-7163.MCT-06-0352 PMID: 17121917.
21. Michael Seckl, Christian Ottensmeier, Michael H. Cullen, Peter Schmid, Lindsay E. James, Christina
Wadsworth, et al. A multicenter phase III randomized double-blind placebo controlled trial of pravastatin
added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC). Journal of
Clinical Oncology, 2013 ASCO Annual Meeting Abstracts Vol 31, No 15_suppl (May 20 Supplement),
2013: 7595. 2013.
22. A. S. Hanbali EUD, D. Wang, M. Jankowski, A. Syed, S. Farhan and R. Chapman. The use of statins
and the effect on survival in patients with small cell lung cancer Journal of Clinical Oncology, 2006
ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 24, No 18S (June 20 Supplement),
2006: 17121. 2006.
23. Lebeau B, Chastang C, Muir JF, Vincent J, Massin F, Fabre C. No effect of an antiaggregant treatment
with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized
clinical trial of 303 patients. The "Petites Cellules" Group. Cancer. 1993; 71(5):1741–5. PMID:
8383578.
24. Ochmanski W. [Influence of antiplatelet drugs (AD) on the efectiveness of combined therapy of small
cell lung cancer. Part II. Influence of treatment on time of remission and patients survival]. Przegl Lek.
2008; 65(7–8):321–8. PMID: 19004228.
Drug Repositioning in Metastatic Small Cell Lung Cancer
PLOS ONE | DOI:10.1371/journal.pone.0144797 January 6, 2016 10 / 11
25. Neal J. 2015 Stanford University. Phase IIa Desipramine in Small Cell Lung Cancer and Other High-
Grade Neuroendocrine Tumors In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of
Medicine (US). [May 26, 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01719861 NLM
Identifier: NCT01719861.
26. JonathanW. Riess NJ, Millie Das, M. Zach Koontz, Pamela Koontz, Heather A, et al. A Drug Reposi-
tioning Study of the Tricyclic Antidepressant Desipramine in Small Cell Lung Cancer and other High-
Grade Neuroendocrine Tumors, Presented at the 15th Annual Targeted Therapies of The Treatment of
Lung Cancer February 18–21 2015, Santa Monica, CA, USA.
27. Barrera I, Spiegel D. Review of psychotherapeutic interventions on depression in cancer patients and
their impact on disease progression. International review of psychiatry. 2014; 26(1):31–43. doi: 10.
3109/09540261.2013.864259 PMID: 24716499.
Drug Repositioning in Metastatic Small Cell Lung Cancer
PLOS ONE | DOI:10.1371/journal.pone.0144797 January 6, 2016 11 / 11
